Experience with biologics for psoriasis in daily practice: rotational therapy is required.
Clarisse
C
Saccomani
Séverine
S
Penz
Raphaelle
R
Guerre-Schmidt
Fabien
F
Pelletier
Eve
E
Puzenat
Marie-Odile
MO
Riou-Gotta
Philippe
P
Humbert
François
F
Aubin
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D057915:Drug Substitution; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept; C472181:efalizumab